• Explore /
  • Poster
  • / Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral <em>EGFR</em> mutations: A systematic review and meta-analysis.

Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.

Abstract Poster

Authors

null

Jonathan N. Priantti

Federal University of Amazonas - UFAM, Manaus, Brazil

Jonathan N. Priantti , Maysa Vilbert , Francisco Cezar A Moraes , Isabella Michelon , Caio Castro , Natasha B. Leighl , Ludimila Cavalcante , Yu Fujiwara , Alfredo Addeo , Jair Bar , Alessio Cortellini , Amin Nassar , Abdul Rafeh Naqash

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8642)

DOI

10.1200/JCO.2024.42.16_suppl.8642

Abstract #

8642

Poster Bd #

506

Abstract Disclosures

Similar Posters

First Author: Shen Zhao

First Author: Li Zhang

First Author: Baolan Li

First Author: Yuangyuan Zhao